ADMA Biologics Quarterly Income Statement
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ADMA Biologics revenue and earnings
In the quarter ended Jun 30, 2026, ADMA Biologics generated $124.4 million in revenue, up 2.0% from the same quarter a year earlier. Net income was $37.8 million (+10.5% year over year), for a net margin of 30.4% versus a median of 28.1% in the prior 5 quarters. Gross margin was 69.4% (up from 55.1%) and operating margin 42.2%.
Diluted earnings per share came in at $0.16, up from $0.14.
Summary generated from market data by MetaCap's automated system. Methodology
ADMA Biologics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 124.39M | 114.49M | 139.16M | 134.22M | 121.98M | 114.80M | 117.55M | 119.84M | 107.19M | 81.88M | 73.90M | 67.28M |
| Revenue growth (YoY) | +1.98% | -0.27% | +18.39% | +12.00% | +13.80% | +40.22% | +59.06% | +78.13% | +78.29% | +43.86% | +47.86% | +63.73% |
| Cost of Revenue | 38.12M | 33.74M | 50.35M | 58.60M | 54.76M | 53.70M | 54.22M | 60.18M | 49.74M | 42.77M | 42.82M | 42.62M |
| Gross Profit | 86.28M | 80.75M | 88.82M | 75.63M | 67.23M | 61.10M | 63.33M | 59.66M | 57.45M | 39.11M | 31.09M | 24.65M |
| Operating Expenses | 33.83M | 22.48M | 26.07M | 24.61M | 24.43M | 26.22M | 25.01M | 20.02M | 18.25M | 17.29M | 16.85M | 15.97M |
| Research & Development | 6.01M | 2.60M | 1.38M | 1.53M | 1.03M | 826.00K | 391.00K | 412.00K | 560.00K | 450.00K | 446.00K | 596.00K |
| Selling, General & Admin | 26.74M | 26.74M | 23.51M | 21.78M | 22.21M | 24.08M | 23.32M | 18.56M | 16.61M | 15.64M | 15.54M | 14.73M |
| Operating Income | 52.45M | 58.27M | 62.75M | 51.01M | 42.80M | 34.88M | 38.32M | 39.64M | 39.20M | 21.82M | 14.23M | 8.69M |
| Interest Expense | 3.42M | 2.10M | 1.63M | 1.68M | 1.83M | 1.98M | 2.88M | 3.50M | 3.78M | 3.77M | 6.21M | 6.40M |
| Other Income (Expense) | -2.21M | -1.15M | -1.16M | -3.50M | -2.70M | -1.43M | -3.61M | -2.89M | -3.35M | -3.42M | -31.88M | -6.12M |
| Pretax Income | 50.24M | 57.13M | 61.59M | 47.52M | 40.10M | 33.45M | 34.71M | 36.75M | 35.85M | 18.40M | -17.64M | 2.56M |
| Income Tax | 12.41M | 11.80M | 12.22M | 11.09M | 5.88M | 6.55M | -77.18M | 840.00K | 3.79M | 595.00K | 0 | 0 |
| Net Income | 37.82M | 45.33M | 49.38M | 36.43M | 34.22M | 26.90M | 111.90M | 35.91M | 32.06M | 17.81M | -17.64M | 2.56M |
| Net Income growth (YoY) | +10.53% | +68.48% | -55.87% | +1.45% | +6.73% | +51.10% | — | +1299.96% | — | — | — | — |
| EPS (Basic) | 0.17 | 0.19 | 0.22 | 0.15 | 0.14 | 0.11 | 0.48 | 0.15 | 0.14 | 0.08 | -0.08 | 0.01 |
| EPS (Diluted) | 0.16 | 0.19 | 0.20 | 0.15 | 0.14 | 0.11 | 0.45 | 0.15 | 0.13 | 0.08 | -0.08 | 0.01 |
| Shares Outstanding (Basic) | 228.23M | 236.07M | — | 238.60M | 241.49M | 237.78M | — | 234.57M | 232.42M | 228.87M | — | 225.28M |
| Shares Outstanding (Diluted) | 230.34M | 239.96M | — | 244.66M | 248.61M | 244.68M | — | 244.80M | 242.17M | 236.41M | — | 233.76M |
| EBITDA | 54.15M | 60.07M | 64.75M | 53.01M | 44.80M | 36.78M | 40.32M | 41.54M | 41.10M | 23.72M | 16.13M | 10.59M |
| Gross Margin | 69.36% | 70.53% | 63.82% | 56.34% | 55.11% | 53.22% | 53.88% | 49.78% | 53.60% | 47.77% | 42.06% | 36.65% |
| Operating Margin | 42.16% | 50.90% | 45.09% | 38.01% | 35.08% | 30.38% | 32.60% | 33.08% | 36.57% | 26.65% | 19.26% | 12.91% |
| Net Margin | 30.40% | 39.59% | 35.48% | 27.14% | 28.05% | 23.44% | 95.19% | 29.96% | 29.91% | 21.75% | -23.88% | 3.81% |
This table shows 12 quarterly periods of ADMA Biologics's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ADMA's reporting calendar. What is a income statement?